

RESEARCH
ARTICLE

-  Faruk Boyacı¹
 Mustafa Kursat Sahin²
 Yankı Boyacı³
 Ahmet Yanık¹
 Gokhan Aksan¹

¹ Department of Cardiology,
Samsun Education and Research
Hospital, Samsun, Türkiye

² Department of Family Medicine,
Ondokuz Mayıs University,
Faculty of Medicine, Samsun,
Türkiye

³ Department of Neurology,
Samsun Education and Research
Hospital, Samsun, Türkiye

Corresponding Author:

Faruk Boyacı

mail: faruk_0601@hotmail.com

Received: 15.04.2023

Acceptance: 22.02.2024

DOI: 10.18521/kt.1282982

Konuralp Medical Journal

e-ISSN1309-3878

konuralptipdergi@duzce.edu.tr

konuralptipdergisi@gmail.com

www.konuralptipdergi.duzce.edu.tr

Comparison of CHA₂DS₂VASc and R₂CHA₂DS₂VASc Score Estimation of In-Hospital Mortality Among COVID-19 Patients

ABSTRACT

Objective: This study aims to compare of CHA₂DS₂VASc and R₂CHA₂DS₂VASc score estimation of in-hospital mortality among COVID-19 patients and find a new scoring system that can better predict the hospital mortality by adding some laboratory parameters to the CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores.

Materials and Methods: This is a cross-sectional study. A total of 1076 COVID-19 patients with confirmed COVID-19 PCR tests were included from September 2020 to March 2021. Age, sex, comorbidity, laboratory, survival times, and death status of the patients were recorded. The scores CHA₂DS₂VASc and R₂CHA₂DS₂VASc of each patient were calculated. A new mortality prediction score was created to establish the most effective model with logistic regression analysis, including laboratory values.

Results: Of the 1076 patients hospitalized for COVID-19, 15.1% died, while 84.9% survived. There was no significant difference between the two groups in sex. All comorbidities were significantly higher in the deceased than in the survivors (p<0.001). The survivors' hemoglobin, thrombocyte, and eGFR values were significantly higher. The C-reactive protein (CRP), aspartate aminotransferase (AST), and neutrophil-to-lymphocyte ratio (NLR) were found to be associated with mortality, and the CAN-R₂CHA₂DS₂VASc score was created by including these three laboratory parameters. The ROC curves of the scores CHA₂DS₂VASc (AUC=0.810), R₂CHA₂DS₂VASc (AUC=0.824), and CAN-R₂CHA₂DS₂VASc (AUC=0.909) were analyzed. The CAN-R₂CHA₂DS₂VASc score was superior to other scores (p<0.001). The sensitivity and specificity of the CAN-R₂CHA₂DS₂VASc score were 79.8% and 86.5%, respectively, while the criterion was >6 points.

Conclusions: The CAN-R₂CHA₂DS₂VASc score is a useful tool for estimating hospital mortality in COVID-19 patients. The CAN-R₂CHA₂DS₂VASc score was superior to the R₂CHA₂DS₂VASc and CHA₂DS₂VASc score in predicting in-hospital mortality.

Keywords: Mortality, Hospitalization, COVID 19, Survival, Risk Factors, Comorbidity.

COVID-19 Hastalarında Hastane İçi Mortalitenin CHA₂DS₂VASc ve R₂CHA₂DS₂VASc Skor Tahmininin Karşılaştırılması

ÖZET

Amaç: Bu çalışma, COVID-19 hastalarında hastane içi mortalitenin CHA₂DS₂VASc ve R₂CHA₂DS₂VASc skor tahminini karşılaştırmayı ve CHA₂DS₂VASc ve R₂CHA₂DS₂VASc skorlarına bazı laboratuvar parametreleri ekleyerek hastane mortalitesini daha iyi tahmin edebilen yeni bir skorlama sistemi bulmayı amaçlamaktadır.

Gereç ve Yöntem: Bu bir kesitsel çalışmadır. Eylül 2020'den Mart 2021'e kadar COVID-19 PCR testleri doğrulanmış toplam 1076 COVID-19 hastası dahil edildi. Hastaların yaş, cinsiyet, komorbidite, laboratuvar, hayatta kalma süreleri ve ölüm durumları kaydedildi. Her hastanın CHA₂DS₂VASc ve R₂CHA₂DS₂VASc skorları hesaplandı. Laboratuvar değerleri de dahil olmak üzere lojistik regresyon analizi ile en etkili modeli oluşturmak için yeni bir ölüm tahmin skoru oluşturuldu.

Bulgular: COVID-19 nedeniyle hastaneye yatırılan 1076 hastanın %15,1'i öldü, %84,9'u hayatta kaldı. İki grup arasında cinsiyet açısından anlamlı fark yoktu. Ölenlerde tüm komorbiditeler yaşayanlara göre anlamlı derecede yüksekti (p<0.001). Hayatta kalanların hemoglobin, trombosit ve eGFR değerleri anlamlı olarak daha yüksekti. C-reaktif protein (CRP), aspartat aminotransferaz (AST) ve nötrofil-lenfosit oranı (NLR) mortalite ile ilişkili bulundu ve bu üç laboratuvar parametresi dahil edilerek CAN-R₂CHA₂DS₂VASc skoru oluşturuldu. CHA₂DS₂VASc (AUC=0,810), R₂CHA₂DS₂VASc (AUC=0,824) ve CAN-R₂CHA₂DS₂VASc (AUC=0,909) skorlarının ROC eğrileri analiz edildi. CAN-R₂CHA₂DS₂VASc skoru diğer skorlardan üstündü (p<0.001). CAN-R₂CHA₂DS₂VASc skorunun duyarlılığı ve özgüllüğü sırasıyla %79,8 ve %86,5 iken, kriter >6 puandı.

Sonuç: CAN-R₂CHA₂DS₂VASc skoru, COVID-19 hastalarında hastane mortalitesini tahmin etmek için yararlı bir araçtır. CAN-R₂CHA₂DS₂VASc skoru, hastane içi mortaliteyi tahmin etmede R₂CHA₂DS₂VASc ve CHA₂DS₂VASc skorundan üstündü.

Anahtar Kelimeler: Ölüm Oranı, Yataklı Tedavi, COVID-19, Sağ Kalım, Risk Faktörleri, Eşzamanlı Hastalık.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was defined as a pandemic by the World Health Organization on 11 March 2020, after its first detection in December 2019 in Wuhan, China, as the causal agent of COVID-19 disease (1, 2). COVID-19 remains a serious health problem worldwide. Although it mainly causes pneumonia in the lung, it can cause illness in more than one organ system (3). Age, male sex, and common cardiovascular comorbidities are associated with worse outcomes, and thromboembolic complications play an important role in the clinical course of these patients (4-6).

SARS-CoV-2 is a single-stranded RNA virus that enters cells by binding to angiotensin-converting enzyme two receptors found mainly in the lungs, heart, and vessels of the human body (7). Endothelial dysfunction is believed to play an essential role in the pathogenesis of thromboembolic events in COVID-19 (8, 9). The SARS-CoV-2 infection has been suggested to induce a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to the formation of intravascular clots in small and larger vessels (10, 11).

The R₂CHA₂DS₂VASc scores, created by combining the CHA₂DS₂VASc score and the estimated glomerular filtration rate (eGFR), are simple scoring systems that are commonly used to predict the risk of systemic thromboembolism in patients with atrial fibrillation (AF) (12, 13). These risk scores have been shown to predict morbidity and mortality in various clinical conditions other than AF (14, 15). Taking into account the worse prognosis of the male sex in COVID-19 patients, it has been shown that the modified CHA₂DS₂VASc score, obtained by assigning 1 point to the male gender instead of the female gender, predicts in-hospital mortality (16-18). Renal dysfunction is also associated with increased morbidity and mortality in COVID-19 patients (19, 20). The R₂CHA₂DS₂VASc score, created by including renal (R) functions in the CHA₂DS₂VASc score, also predicts mortality in COVID-19 patients (16, 21). Similar to these, many other scoring systems have been created, including clinical, laboratory, and physiological parameters (20, 22-24). COVID-19 is a systemic infectious disease that causes cell destruction and inflammation. A new scoring system in which laboratory values that indicate cell damage and inflammation are included will be more effective in determining the prognosis. The aim is to compare CHA₂DS₂VASc and R₂CHA₂DS₂VASc score estimation of in-hospital mortality among COVID-19 patients and find a new scoring system that can better predict hospital mortality by adding some laboratory parameters to the CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores.

MATERIAL AND METHODS

This retrospective study was conducted at Health Sciences University Samsun Training and Research Hospital and included 1200 consecutive patients whose COVID-19 nasopharyngeal swab samples were positive by real-time reverse transcriptase-polymerase chain reaction (PCR) between September 1, 2020 and March 31, 2021. Those with active cancer, those receiving chemotherapy-radiotherapy treatment, immunosuppressive therapy for various reasons, those with severe liver disease, coagulation disorders, rheumatological diseases (Systemic Lupus Erythematosus, Behçet's Syndrome, Rheumatoid Arthritis, etc.), those using oral contraceptives and those

aged under 18 years were excluded from the study. A total of 1076 patients with COVID-19 who met the appropriate criteria were included in the study. This study was carried out according to the Declaration of Helsinki, registered with the Ministry of Health Scientific Research COVID-19 Committee, and approved by the Local Ethics Committee.

Demographic, laboratory, and clinical information was obtained from patient electronic data at the emergency department and COVID-19 clinics, accessible at the individual patient level. Demographic and clinical data included age, sex, presence of prior diabetes mellitus, hypertension, hyperlipidemia, congestive heart failure, cardiovascular disease, chronic obstructive pulmonary disease (COPD), cerebrovascular disease, chronic kidney disease, and smoking status. Detailed biochemical data and complete blood counts of all patients were obtained from the emergency department and the COVID-19 clinics. The estimated glomerular filtration rate (eGFR) was calculated using the Modified Diet in Renal Disease equation in kidney disease, using the mean of two different serum creatinine measurements in patients with steady-state renal function (one on emergency room admission and the second on the first day of pandemic hospital admission). Patients with acute kidney damage were excluded and an eGFR value <60 ml/min/1.73 m² was accepted as renal failure.

The CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores of each patient were calculated during their hospitalization using clinical data from electronic medical health record history and routine biochemical tests. CHA₂DS₂VASc was calculated by giving 1 point for congestive heart failure, hypertension, age 65-74 years, diabetes mellitus, vascular disease, male sex, and 2 points for ischemic stroke history and/or transient ischemic attack (TIA) and age ≥75 years. When calculating the M-R₂CHA₂DS₂VASc score, the eGFR values >60 ml/min/1.73m², between 30-60 ml/min/1.73 m² and <30 ml/min/1.73m² were determined to be 0, 1 and 2 points, respectively. In addition to the CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores, binary logistic regression analysis was used to select laboratory variables affecting the risk of in-hospital mortality. Parameter estimates were obtained using the stepwise selection method to identify the most effective model and variables that included all possible variations.

C-reactive protein (CRP) levels were evaluated according to the classification of 3-10 mg/L normal or minor elevation, 10-100 mg/L moderate elevation, and >100 mg/L marked elevation (25). These levels were evaluated as 0, 1, 2 points, respectively. Aspartate aminotransferase (AST) levels were evaluated as < 40 U/L normal, 40-80 U/L mild elevation, and >80 U/L moderate or marked elevation (26). These levels were evaluated as 0, 1, and 2 points, respectively. Since there is no standardized classification for AST value, an increase of 2 times the upper limit of normal was evaluated as moderate or marked. The Neutrophil/Lymphocyte ratio (NLR) was evaluated according to the classification of <6 normal, 6-9 mild stress, >9 critically ill patients (27). These levels were evaluated as 0, 1, and 2 points, respectively.

Statistical Analysis: Statistical analysis was performed using The conformity of continuous variables to the normal distribution was examined using visual graphics and the Kolmogorov-Smirnov/Shapiro-Wilk test. Continuous variables were presented as median

(quartile 1- quartile 3) and categorical variables as frequency and percentage. When appropriate, categorical variables were analyzed using the chi-square or Fisher's exact test. Continuous variables were analyzed using the Mann-Whitney U test.

In addition to the CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores, binary logistic regression analysis was used to select laboratory variables affecting the risk of in-hospital mortality. Parameter estimates were obtained using the stepwise selection method to identify the most effective model and the variables that included all possible variations. Cox & Snell R², Nagelkerke R², accuracy, and p-values of the CAN-R₂CHA₂DS₂VASc model created in this way were evaluated. The significance level was accepted as p<0.05. IBM SPSS Statistics version 26.0. was used for these analyses.

Receiver operating characteristic (ROC) analysis was performed for scores. The area under the curve (AUC) was evaluated. AUC and 95%CI values were given. The Delong test was used for the comparison of the ROC curve. The point of criterion at which sensitivity and specificity were optimal was selected using the Youden index. MedCalc® Statistical Software trial version 20.115 (MedCalc Software Ltd, Ostend,

Belgium; <https://www.medcalc.org>; 2022) was used for these analyses.

RESULTS

While 15.1% (n=163) of 1076 patients hospitalized for COVID-19 died, 84.9% (n=913) survived. There were no significant differences between the two groups in sex, and 46.3% of the survivors and 41.7% of the deceased were women (p=0.276). There was a significant difference between survivors and deceased in terms of age (p<0.001). While 43.6% of the deceased were ≥75 years old, 27.6% were in the 65-74 age range, and 28.8% were in the 18-64 age range. On the other hand, 66.0% of the survivors were in the 18-64 age range. Of those who died, 28.8% had congestive heart failure, 85.3% hypertension, 14.7% Stroke/TIA/thromboembolism, 33.1% vascular disease, 50.9% diabetes, 57.1% chronic renal failure, and 17.8% COPD comorbidity. All comorbidities were significantly higher in the deceased than in the survivors (p<0.001). Initial laboratory evaluation revealed that the survivors' hemoglobin, thrombocyte, and eGFR values were significantly higher. In contrast, all other laboratory parameters in Table 1 were significantly higher in the deceased.

Table 1. Characteristics and initial laboratory results of COVID-19 patients

Parameters	Survivor n=913	Non-survivor n=163	p-values
Sex (Female), n (%)	423(46.3)	68(41.7)	0.276
Age group, n (%)			
18-64 years	603(66.0)	47(28.8)	<0.001
65-74 years	201(22.0)	45(27.6)	
≥75 years	109(12.0)	71(43.6)	
Comorbidities, n (%)			
Congestive heart failure	48(5.3)	47(28.8)	<0.001
Hypertension	393(43.0)	139(85.3)	<0.001
Stroke/TIA/thromboembolism	15(1.6)	24(14.7)	<0.001
Vascular disease	109(11.9)	54(33.1)	<0.001
Diabetes	242(26.5)	83(50.9)	<0.001
Chronic kidney disease	156(17.1)	93(57.1)	<0.001
COPD	57(6.2)	29(17.8)	<0.001
Initial laboratory results, Median (q1-q3)			
White Blood Cell (x10 ³ /μL)	6.2 (4.8-8.0)	8.1 (5.6-11.1)	<0.001
Hemoglobin (g/dL)	13.1 (12.0-14.2)	12.0 (10.8-13.0)	<0.001
Platelet (x10 ³ /μL)	211.0 (167.0-270.0)	184.0 (145.0-245.0)	<0.001
NLR	3.5 (2.4-5.2)	8.0 (5.0-11.0)	<0.001
Glucose (mg/dL)	124.0 (111.0-158.0)	163.0 (127.0-248.0)	<0.001
AST (U/L)	40.0 (32.0-52.0)	66.0 (45.0-89.0)	<0.001
ALT (U/L)	32.0 (23.0-45.0)	47.0 (35.0-70.0)	<0.001
eGFR (ml/dk/1,73m ²)	83.0 (67.0-98.0)	56.0 (36.5-75.6)	<0.001
BUN (mg/dL)	32.0 (25.0-41.0)	60,0 (45.0-85.0)	<0.001
Creatinine (mg/dL)	0.9 (0.8-1.0)	1.2 (0.9-1.7)	<0.001
BUN/Creatinine	16.9 (14,5-19.6)	21.5 (18.9-27.6)	<0.001
CRP (mg/L)	55.0 (30.0-100.0)	130.0 (88.0-185.0)	<0.001
Ferritin (mcg/L)	300.0 (167.0-490.0)	650.0 (345.0-953.0)	<0.001
D-dimer (mcg/mL)	0.7 (0.5-1.1)	1.4 (0.9-2.4)	<0.001
Fibrinogen (mg/dL)	450.0 (347.0-543.0)	519.0 (450.0-600.0)	<0.001
Troponin I (ng/mL)	0.1 (0.0-0.1)	0.2 (0.1-0.6)	<0.001
Creatine Kinase MB (ng/mL)	1.0 (0.9-2.0)	4.0 (3.0-6.0)	<0.001

TIA: transient ischemic attack; COPD: Chronic obstructive pulmonary disease; NLR: Neutrophil to lymphocyte ratio; AST: Aspartate aminotransferase; ALT: Alanine Aminotransferase; eGFR: Estimated glomerular filtration rate; BUN: Blood Urea Nitrogen; CRP: C-reactive protein

The stepwise logistic regression models in Table 1, which include all laboratory values not used in R₂CHA₂DS₂VASc scoring, attempted to identify the most important factors explaining mortality. In these models, there were 3 variables other than R₂CHA₂DS₂VASc in the model with the highest mortality explanation rate, and other criteria were excluded from the model because they decreased the model's mortality explanation rate. The C-reactive protein (CRP), aspartate aminotransferase (AST), and neutrophil-to-lymphocyte ratio (NLR) were found to be associated with mortality (Table 2). A new scoring system was created by adding these three new laboratory values associated with mortality to the current scoring system (Table 3). The CAN-R₂CHA₂DS₂VASc score was established by

assigning letter C for C-reactive protein (CRP), letter A for aspartate aminotransferase (AST), and letter N for neutrophil to lymphocyte ratio (NLR) (Table 3).

Table 2. Regression analysis of the predictive model for COVID-19 patients (CAN-R₂CHA₂DS₂VASc)

Predictive Model	OR (95%CI)	p
R ₂ CHA ₂ DS ₂ VASc	1.901 (1.686-2.144)	<0.001
NLR	1.207 (1.131-1.289)	<0.001
AST	1.009 (1.006-1.013)	<0.001
CRP	1.020 (1.014-1.027)	<0.001

Model fit: p < 0,001; Cox & Snell R²= 0,3051; Nagelkerke R²= 0,5326; Accuracy=90%

Table 3. Criteria of CAN-R₂CHA₂DS₂VASc

Criteria	Category	Points
Congestive heart failure history		+1
Hypertension history		+1
Age	<65 years old	0
	65-74 years old	+1
	≥75 years old	+2
Diabetes mellitus history		+1
Previous stroke, transient ischemic attack, thromboembolism history		+2
Vascular disease history (prior myocardial infarction, peripheral artery disease, or aortic plaque)		+1
Sex	Female	0
	Male	+1
Renal Function (estimated glomerular filtration rate (eGFR)) (ml/dk/1,73m ²)	> 60	0
	30-60	+1
	<30	+2
CRP (mg/L)	<10	0
	10-100	+1
	>100	+2
AST (U/L)	<40	0
	40-80	+1
	>80	+2
NLR	<6	0
	6-9	+1
	>9	+2

AST: Aspartate aminotransferase; CRP: C-reactive protein; eGFR: Estimated glomerular filtration rate; NLR: Neutrophil to lymphocyte ratio;

ROC curves of CHA₂DS₂VASc, R₂CHA₂DS₂VASc, and CAN-R₂CHA₂DS₂VASc scores were analyzed (Figure 1). The area under the curve (AUC) was calculated as 0.810 for CHA₂DS₂VASc, 0.824 for R₂CHA₂DS₂VASc, and 0.909 for CAN-R₂CHA₂DS₂VASc. The Delong test was used for the comparison of the ROC curve. The AUC of the R₂CHA₂DS₂VASc score was significantly higher than the CHA₂DS₂VASc score (p=0.009).

The AUC of the CAN-R₂CHA₂DS₂VASc score was significantly higher than the AUC of both R₂CHA₂DS₂VASc and CHA₂DS₂VASc scores (p<0.001). The point of criterion at which sensitivity and specificity were optimal was selected using the Youden index. The CAN-R₂CHA₂DS₂VASc score sensitivity was 79.8%, specificity was 86.5%, +LR was 5.92, -LR was 0.23, while the criterion was >6 points (Figure 2).




Figure 1. Comparison of Scores' ROC curves for survivors.




Figure 2. ROC curve of the CAN-R₂CHA₂DS₂VASc scores, sensitivity, specificity, and criterion.

DISCUSSION

Although COVID-19 was initially thought to be primarily a respiratory disease, evidence suggests that the primary and perhaps most important target of the virus is the endothelium. Endothelial dysfunction is believed to play an important role in the pathogenesis of thromboembolic events in COVID-19. (8, 9) COVID-19 has been suggested to induce a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to the formation of intravascular clots in small and larger vessels (10, 11). Endothelial hemostasis plays a vital role in the regulation of fibrinolysis and vessel wall permeability, and its dysfunction triggers immunothrombosis (10, 11, 28). Endothelial dysfunction is associated with atherosclerotic risk factors such as diabetes mellitus, hypertension, hyperlipidemia, inflammation, coronary artery disease, and peripheral artery disease (29, 30). Comorbidities such as diabetes mellitus, hypertension, and cardiovascular disease associated with endothelial dysfunction have been found to be more common in hospitalized patients with COVID-19. These comorbidities have also been observed to be associated with a predisposition to severe COVID-19 and an increased risk of death (31-33).

The CHA₂DS₂VASc score and R₂CHA₂DS₂VASc score, which is formed by including the estimated glomerular filtration rate (eGFR), are simple scoring systems that are commonly used to predict the risk of systemic thromboembolism in patients with AF (10, 11). These scores are primarily designed to predict the risk of thrombosis, and many of their components are also prognostic risk factors for COVID-19. As the patients' CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores increase, their susceptibility to endothelial dysfunction and thrombosis increases. Since endothelial dysfunction and thrombosis play an important role in the pathogenesis of COVID-19, these scores were thought to predict in-hospital mortality in this patient population (9, 10). Studies have shown that in COVID-19 patients, the CHA₂DS₂VASc and R₂CHA₂DS₂VASc obtained by scoring the male sex predicts in-hospital mortality (16-18, 21).

This study supports previous studies. Both the CHA₂DS₂VASc and R₂CHA₂DS₂VASc scores demonstrated increased in-hospital mortality. Some studies have shown that renal dysfunction is associated with increased morbidity and mortality in COVID-19 (19, 20). In light of these studies, we investigated whether the R₂CHA₂DS₂VASc score, which was created by including eGFR in the CHA₂DS₂VASc score, was superior in predicting mortality, since kidney functions are an important cause of mortality in this population of patients. As a result, the R₂CHA₂DS₂VASc score was superior

to the CHA₂DS₂VASc score in terms of mortality prediction.

Since COVID-19 is a systemic infectious disease, it causes destruction and increases cell inflammation. Therefore, it is not surprising that the CRP, AST, and NLR values increase in COVID-19 patients. Studies have shown that inflammatory markers such as CRP and NLR are associated with increased mortality in COVID-19 (34-37). Significant increases in AST have also been reported in COVID-19 patients. The increase in AST, which is found not only in the liver but also in many organs, can be explained by the resulting multiorgan dysfunction (38-40). In the model created with the CRP, AST, and NLR values added to the R₂CHA₂DS₂VASc score, and it was possible to evaluate endothelial dysfunction and thrombosis together with cell destruction and inflammation parameters.

Consequently, early estimation of the risk of death in COVID-19 patients is of great importance in terms of clinical patient management and treatment strategies, and we found that the ability of the CAN-R₂CHA₂DS₂VASc score to predict mortality is better than the R₂CHA₂DS₂VASc and CHA₂DS₂VASc scores. *The CAN-R₂CHA₂DS₂VASc score we defined had sufficient sensitivity and specificity and was more successful in predicting mortality.* Unlike other scores, it includes both clinical and laboratory parameters, making it a strong prognostic indicator.

This study has some limitations. First, this study is a retrospective and single-center study. This may limit the generalizability of this study's findings. Furthermore, this study was carried out in the early period of the pandemic, when variants of COVID-19 (delta, omicron, etc.) had not yet emerged and vaccination had not started in Türkiye. Different viral strains and vaccination status can influence the risk of complications and prognosis among infected patients. The performance of this new scoring system may differ between currently infected patients with different viral strains and vaccination status. Due to increased vaccinations and newly emerging variants, the efficacy of this model must be tested in a population of new dominant variants. Racial differences may also affect the severity and prognosis. The generalizability of the results and the usability of the score in clinical practice should be evaluated with larger studies.

CONCLUSION

The results of this study showed that the CAN-R₂CHA₂DS₂VASc score could be useful in predicting in-hospital mortality in patients with COVID-19. Furthermore, the predictive ability of CAN-R₂CHA₂DS₂VASc was better than the R₂CHA₂DS₂VASc and CHA₂DS₂VASc scores to predict mortality in this patient population. Since it is an easily calculable score, it can help determine clinical patient management and treatment strategies by estimating the risk of mortality early.

REFERENCES

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun.* 2020;109:102433.
2. World Health Organization. Coronavirus disease (COVID-19): situation report, 209. 2020.
3. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Virol.* 2020;127:104371.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
5. Zerwes S, Steinbauer M, Gosslau Y, Warm T, Hyhlik-Durr A. [COVID-19 infection-Risk of thromboembolic complications]. *Gefasschirurgie.* 2020;25(6):397-402.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62.
7. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2020;75(23):2950-73.
8. Barbosa LC, Goncalves TL, de Araujo LP, Rosario LVO, Ferrer VP. Endothelial cells and SARS-CoV-2: An intimate relationship. *Vascul Pharmacol.* 2021;137:106829.
9. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020;395(10234):1417-8.
10. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res.* 2020;220:1-13.
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020;8(4):420-2.
12. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation.* 2013;127(2):224-32.
13. van Doorn S, Debray TPA, Kaasenbrood F, Hoes AW, Rutten FH, Moons KGM, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. *J Thromb Haemost.* 2017;15(6):1065-77.
14. Kiliszek M, Szpakowicz A, Filipiak KJ, Koltowski L, Poludniewska D, Szymanski F, et al. CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. *Pol Arch Med Wewn.* 2015;125(7-8):545-52.
15. Kim KH, Kim W, Hwang SH, Kang WY, Cho SC, Kim W, et al. The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. *J Cardiol.* 2015;65(2):121-7.
16. Levy D, Gur E, Topaz G, Naser R, Kitay-Cohen Y, Benchetrit S, et al. Mortality prediction using a modified R(2)CHA(2)DS(2)-VASc score among hospitalized COVID-19 patients. *Intern Emerg Med.* 2022;17(6):1711-7.
17. Cetinkal G, Kocas BB, Ser OS, Kilci H, Keskin K, Ozcan SN, et al. Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized With COVID-19. *Am J Cardiol.* 2020;135:143-9.
18. Caro-Codon J, Lip GYH, Rey JR, Iniesta AM, Rosillo SO, Castrejon-Castrejon S, et al. Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. *Europace.* 2021;23(6):937-47.
19. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. *Nat Rev Nephrol.* 2020;16(12):705-6.
20. Trabulus S, Karaca C, Balkan, II, Dincer MT, Murt A, Ozcan SG, et al. Kidney function on admission predicts in-hospital mortality in COVID-19. *PLoS One.* 2020;15(9):e0238680.
21. Katkat F, Karahan S, Varol S, Kalyoncuoglu M, Okuyan E. Mortality prediction with CHA2DS2-VASc, CHA2DS2-VASc-HS and R2CHA2DS2-VASc score in patients hospitalized due to COVID-19. *Eur Rev Med Pharmacol Sci.* 2021;25(21):6767-74.
22. Velissaris D, Paraskevas T, Oikonomou E, Bizos A, Karamouzou V, Marangos M. Evaluation of four novel prognostic scores on admission for COVID-19 mortality. An experience from a Mediterranean tertiary center. *Acta Clin Belg.* 2022;77(4):748-52.

23. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ*. 2020;370:m3339.
24. Covino M, De Matteis G, Burzo ML, Russo A, Forte E, Carnicelli A, et al. Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. *J Am Geriatr Soc*. 2021;69(1):37-43.
25. Nehring SM, Goyal A, Patel BC. C Reactive Protein. *StatPearls*. Treasure Island (FL) ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. Disclosure: Bhupendra Patel declares no relevant financial relationships with ineligible companies.2024.
26. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. *CMAJ*. 2005;172(3):367-79.
27. Man MA, Davidescu L, Motoc NS, Rajnoveanu RM, Bondor CI, Pop CM, et al. Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) in Various Respiratory Diseases: A Retrospective Analysis. *Diagnostics (Basel)*. 2021;12(1).
28. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. *Nat Rev Nephrol*. 2021;17(1):46-64.
29. Choi BJ, Matsuo Y, Aoki T, Kwon TG, Prasad A, Gulati R, et al. Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2014;34(11):2473-7.
30. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. *Glob Cardiol Sci Pract*. 2014;2014(3):291-308.
31. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
32. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*. 2020;323(18):1775-6.
33. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-9.
34. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. *Ann Clin Microbiol Antimicrob*. 2020;19(1):18.
35. Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis. *Cytometry A*. 2020;97(8):772-6.
36. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *J Med Virol*. 2020;92(10):1733-4.
37. Wang L. C-reactive protein levels in the early stage of COVID-19. *Med Mal Infect*. 2020;50(4):332-4.
38. Aloisio E, Colombo G, Arrigo C, Dolci A, Panteghini M. Sources and clinical significance of aspartate aminotransferase increases in COVID-19. *Clin Chim Acta*. 2021;522:88-95.
39. Li G. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19. *J Infect*. 2020;81(2):e155.
40. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol*. 2020;5(5):428-30.